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ABSTRACT 
 
One of the vital process by which cellular homeostasis is maintained is Apoptosis. In 
normal cells this program is well balanced. But any alteration in genetic and epigenetic process 
leads to loss of key properties like proliferation, differentiation, invasion, adhesion, and hence 
opened thegateway for complex set of disease known as cancer. Moreover, RAS/MEK/ERK and 
PI3K/AKT signaling cascade is the most frequently mutated pathway in human cancer. 
Oncogenic mutations in these cascade leads to deregulation of several effecter pathways that 
control cell proliferation, survival, apoptosis as well migration, and thus promote malignant 
transformation. As all natural polyphenols have anti- cancer property to some extent, we aimed 
at investigating the effect of natural polyphenols like curcumin and EGCG in combination with 
other conventional chemotherapeutic agents which are used a lot in epigenetic targeted therapies, 
potentially working synergistically in increasing the therapeutic effect of drugs in combat against 
cancer. So the present study aims at deciphering the role of curcumin and EGCG on the 
induction of apoptosis, inhibition of cell proliferation and change in expression level of 
oncogenes K-Ras and Akt1 in breast cancer cell lines. A brief study can help to pile valuable 
information for developing better therapeutic interventions against cancer. 
Key words:  apoptosis, cancer, natural polyphenols, curcumin, EGCG, K-Ras, Akt1 
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INTRODUCTION 
Body is made up of trillion of living cells which grows, divides and dies in regular 
fashion to maintain cellular homeostasis. Aberration in any of the vital process due to diseased 
condition leads to the loss of  key properties like proliferation, differentiation, invasion,adhesion 
etc. resulting in rise of a complex set of  disease known as cancer. Various factors are 
responsible for onset of tumorogeneis like deletion, mutation, chromosome rearrangements etc. 
These alterations are broadly classified under two heads, one is genetic and the other is 
epigenetic mechanism.In normal cells homeostasis is achieved by maintaining a proper balance 
between cell death and proliferation but in cancer cell there is evasion of cell death which 
enhances the survivability of these cells as compared to normal ones. Various signaling pathways 
act in cohort to orchestrate the evasion of cell death in cancer cells like PI3/AKT and 
RAS/MEK/ERK pathways. Genes of PI3K/AKT and RAS/MEK/ERK pathway are mutated in 
such a way that they remain in permanently turn “on” state leading to the survival of cells when 
it is no longer needed and thus inhibiting apoptosis. This causes cancer in combination with other 
lethal mutations. Besides these, epigenetic alterations like DNA methylation at promoter region 
or post translational histone modification may lead to either suppression of tumor suppressor 
genes or activation of oncogenes. Thus any defect in genome, including both genetic and 
epigenetic alterations causes the development of cancer. It can affect almost any part of the body 
giving rise to myriad forms of cancer like lung cancer, breast cancer, colon cancer, prostate 
cancer, pancreatic cancer etc. Out of these, Breast cancer is one of the major causes of women 
mortality in United States than any other cancer except lung cancer. It accounts for 22.9% of all 
cancers in women throughout the world causing 16% of all female cancers deaths worldwide. 
Every year approximately 200,000 women and 2,000 men are diagnosed with breast cancer 
(http://www.cancer.org) so it is 100 times more common in women than in men. Day by day 
number of deaths caused by breast cancer in western countries is increases rapidly so it is 
necessary to take some appropriate and required steps to improve the treatment. With the 
advancement of science and technology many drugs like temoxifen, transtuzumab etc. and other 
effective ant- cancer therapeutics are introduced and worldwideadopted,resulting in decrease in 
mortality rate caused by breast cancer. At present besides these conventional chemotherapeutic 
agents natural polyphenols are also used a lot in epigenetic targeted therapies in human trials 
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potentially working synergistically in increasing the therapeutic effect of drugs in combat against 
cancer.  
Therefore the present study aims at deciphering the role of natural polyphenols like 
curcumin and EGCG on the induction of apoptosis, inhibition of cell proliferation and change in 
gene expression of K-Ras and Akt1in breast cancer cell lines. A brief study can help to pile 
valuable information for developing better therapeutic intervention against cancer. 
Ras is a guanosine nucleotide binding protein belonging to a class of protein named as 
small GTPase which involves in signal transduction within the cells. It regulates variety of 
biological processes that includes cell proliferation, differentiation and apoptosis. RAS and RAS 
related protein may also deregulated in cancers leading to increase in metastasis and invasion and 
decreasing apoptosis.It activates many pathways out of which MAP kinase pathway is well 
studied which transmit downstream signals resulting in transcription of genes involved in cell 
growth and cell division. It also activates AKT pathway which inhibits apoptosis. 
Two forms of Ras H-Ras and K-Ras originally studied in rats during 1960s by Jennifer 
Harvey and Werner Kirsten respectively and named as Rat Sarcoma and then were discovered 
byGeoffrey M. Cooper at Harvard in human cells in 1982. Third Ras gene named N-RAS was 
identified in human neuroblastoma cells. The three form of human RAS i.e. H-Ras, K-Ras, N-
Ras encodes a similar proteins which constitutes 188-189 amino acids.All Ras gene contains six 
stranded beta sheets and five alpha helices. These three human genes function as molecular 
switches in “on and off” states controlling intracellular network signaling. When it is bound to 
inactive guanosine diphosphate (GDP) it is in “off state” while in “on state” when it is bound to 
guanosine triphosphate (GTP). Guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs) facilitate the switching between active GTP and inactive GDP. The 
whole mechanism is shown in fig 1. 
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Fig1: G- protein regulation 
 
RAS/MEK/ERK signaling pathway: 
Raf serine/ threonine kinase is the best downstream effector target of RAS. When GTP 
binds to RAS, activates a protein kinase, Raf-1 which phosphorylates MEK on two serine 
residues and activates it. MEK activation phosphorylates ERK on Thr and Tyr residues and 
activates it. Activated EKR enters inside the nucleus and phosphorylates nuclear transcription 
factor Elk1 and finally activates it. This activated Elk1 joins to serum responsefactor (SRF) to 
stimulate the transcription and translation of a set of genes considered necessary for cell division.  
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Fig2: RAS/MEK/ERK pathway 
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PI3K/AKT pathway: 
 
The major component of cell membrane in eukaryotes is Phosphatidylinositol. 
Phosphatidylinositide kinase pohosphorylates the inositol head of phospholipid which helps in 
signal transduction involved in regulation of multiple cellular functions.Phosphatidylinositol 3-
kinases (PI3K) having catalytic subunit p110 and regulatory subunit p85, which involves in cell 
growth, proliferation, differentiation, survival and motility, ultimately cause cancer.  It can be 
activated by two pathways. In first pathway it reacts with growth factor receptors having 
phosphorylated tyrosine residues. As a result conformational changes occur indimmers resulting 
in activation of PI3. Second pathway is direct binding of PIP3 to catalytic subunit p110 via 
Ras.PI3Kare the second most characterized Ras effecter. It is a lipid kinaseand activated by a 
transmembrane signal, converting phosphatidylinositol 4, 5 bisphosphate(PIP2) to 
phosphotidylinositol 3,4,5trisphosphate (PIP3). This PIP3 recruits Akt and PDK1 to plasma 
membrane to activate downstream signaling components. When it bound toPIP3, Akt is 
phosphorylated and activated by phosphoinositide dependent kinase (PDK). Once Akt is 
activated, it can modulatenumerous substrates and regulate multiple cellular events like cell 
cycle progression, cell growth, cell survival, apoptosis, transcription etc by binding with 
downstream effectors like nuclear factor kB, BCl2 family etc. Akt could phosphorylate a pro- 
apoptotic protein BAD which is a member of BCl2 on its Ser136 residue, dissociating it from 
Bcl-2/Bcl-X complex as a result lose its pro-apoptotic function. It also activates NFkB by 
regulating IkB kinase (IKK) which results in the transcription of pro survival genes. Out of three 
isoforms of Akt i.e Akt1, Akt2, Akt3, Akt1 inhibits apoptosis and thus involved in cellular 
survival pathways. It has been shown that it is a critical player in oncogenesis. p85 subunit of 
Akt binds with the activated epidermal growth factor receptor kinase protein specially HER2 or 
mutational inactivation or the deletion of PTEN tumor suppressor gene results in increased 
kinase activity. 
 
 
 
 
 
 
 6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig3: PI3/AKT/mTOR pathway activation 
 
EPIGENETIC MODULATORS: 
Various diseases and behavioral pathologies are emerging due to defect in gene functions and 
the well known example is cancer. By changing the sequence of DNA or by changing the 
epigenetic programming of a gene without changing the DNA sequence one can change the 
function of a gene. Epigenetic modulators can be used to revertsuch aberrant gene expression 
bytargeting DNA methylation, Histone acetylation, histone deacetylation, histone methylation, 
signatures. Till now only few drugs like curcumin, SAHA, SAM, TSA, EGCG etc. have shown 
success in clinical trials. 
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CURCUMIN as an epigenetic modulator: 
Curcumin is a diarylheptanoid, a member of zingiberaceaefamily extracted from the 
rhizomes of Curcuma longais a naturally occurring phytochemical receiving attention from the 
investigators working in field of tumorigenesis. It inhibits growth, invasion and metastasis of 
tumor cells, inducing apoptosis and sensitizing the tumor cells towards chemotherapeutic 
drugs.It is a polyphenol component also having antioxidant and anti-mutagenicproperties and 
exists in several tautomericforms. The enol form is energetically more stable than compared to 
ketoform. The general formula is 1, 7-Bis (4-hydroxy-3-methoxyphenyl) 1, 6-heptadiene-
3,5dione. 
 
 
                                
 
              Enol form                                                                              keto form 
 
Fig4:Structure of curcumin 
 
 
Curcumin could exert its biological activities even at low concentration through 
epigenetic modulation. It act as DNA methyltransferase inhibitor and hence known as DNA 
hypomethylating agent. It can block the catalytic thiolate of DNMT1 with the IC50 of 25 µM 
leading to an inhibition of DNA methylation [1]. It also renew the balance between histone 
acetyltransferase activity to activate and histone deacetylase(HDAC 1, 3, 4, 5, 8)activity to 
inactivate the expression of genes implicated in cancer death and progression. It can suppress the 
HDAC-i activated tumor development proteins and cell migration in vitro on combining with 
HDAC inhibitor [1].Besides this it can modulate miRNAs(miR-15a, miR-16, miR-21, miR-22, 
miR-26, miR-101, miR-146, miR-200, miR-203, and let-7) and their multiple taregetgenes [1].In 
case of breast cancer and leukemia cancer cell line it was found that it upregulates the expression 
of miR-15a, miR-16 leading to decline the expression level of anti-apoptotic Bcl-2 gene[1]. 
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TABLE 1:Overview of Epigenetic effect of curcumin and their biological incidence in different 
cancer cell lines 
 
 
TUMOR 
TYPE 
 
CELL 
LINES 
TYPES OF 
EPIGENETIC 
MODULATION 
 
BIOLOGICAL INCIDENCE 
 
REFERENCE 
Breast 
cancer 
 
MCF 7 cells 
 
DNA 
methylation 
 
DNA hypomethylation by DNMT1 
regulation at mRNA and protein 
level 
 
[2] 
Cervical 
cancer 
 
HeLa cells 
 
Histone 
modification 
 
Inhibition of p300/CREB-binding 
protein(CBP) HAT activity 
 
[3] 
 
HeLa cells 
 
Histone 
modification 
 
HDAC inhibition, molecular 
docking 
of curcumin with HDAC8 
 
[4] 
Prostate 
cancer 
 
LNcaP cells 
 
DNA 
methylation 
 
DNA hypomethylation: reversion 
of 
CpG methylation of the promoter 
region of Neurog1/DNMT 
inhibition 
 
[5] 
 
PC3 cells 
 
Histone 
modification 
 
Inhibition of histone 
hyperacetylation/promotion of 
proteasome-dependent 
degradation of p300 
 
[6] 
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EGCG as an epigenetic modulator: 
 
Epigallocatechin gallate (EGCG)is the ester of epigallocatechin and gallic acid, the most 
abundant catechin in tea and a major polyphenol in green tea having therapeutic application in 
the treatment of many diseases like cancer, HIV infectionand studied as a potential 
demethylating agent.The general formula of EGCG is 5,7-dihydroxy-2-(3,4,5-
trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate.  
 
 
 
Fig 5: Structure of EGCG 
 
It is the most potent inhibitor of catechol- O-methyltransferase activity[7]. Catechol-O-
methyltransferase and DNMT belong to the same superfamily of S adenosylmethionine 
dependent methyltransferase. At the catalytic site these two enzymes have a common core 
structure that enhances the possibility of EGCG to inhibit DNMT by binding to a similar 
catalytic site [8]. Thus it acts as a DNMT inhibitor. It also induces the hypoacetylation of p65by 
inhibiting the activity of HAT enzymes leading to the down-regulation of NF-κB function by 
diverse inflammatory signals. Thus EGCG also acts as an inhibitor of HAT [9].Besides these 
EGCG modulates the expression of miRNA in human hepatocellular carcinoma HepG2 cells 
[10].  
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REVIEW OF LITERATURE 
 
 
RAS GENE MUTATION AND CANCER: 
 
 Oncogenic mutation disrupts the signaling cascade and regulatory circuit involved in cell 
fate, endowing tumor cells to maintain their malignant behavior. It is reported that besides six 
hallmarks (shown in figure) of cancer cells like self sufficiency or the stimulation in their own 
growth, insensitive or resistant to inhibitory signals that halts their growth, self ability to limitless 
replication, tolerate their own programmed death (apoptosis), maintenance of angiogenesis, and 
tissue invasion (metastasis), metabolic fitness and genomic instabilityalso contribute in tumor 
malignancy.Cell signaling studies revealed the mechanism which induce oncogenic mutation and 
maintain the cardinal aberrations. 
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Fig 6: Hallmarks of cancer 
 
RAS proteins are the indispensable components of transduction pathway that controls 
cellular proliferation, differentiation, or survival. Mutation in any one of the canonical H-Ras, K-
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Ras, and N-Ras genes can produce RAS proteins which are permanently activated ultimately 
causes in cancer. 
Upto 30% of all human tumors are caused due to alteration in canonical Ras gene isoform 
[11]. Oncogenic K-Ras mutations being recognized in 25-30% of all screened tumor samples 
shows that predominantly affect the K-Ras locus are predominantly oncogenic mutated [11].This 
high frequency of K -Ras mutation supports its causative role in human tumorigeneis but the rate 
of oncogenic mutation in N-Ras and H-Ras were screened in sample much lower i.e 8% and 3% 
of respectively [11].This data was confirmed and represented by the catalogue of somatic 
mutations in cancer (COSMIC). In human cancers a great variety of oncogenic Ras mutations are 
found, about 90% of tumors in pancreatic ductal adenocarcinoma were harbored by K-Ras 
isoform, in contrast bladder, malignant melanoma, thyroid and mammary carcinomaby H-Ras 
mutation and in hematopoietic tumors K-Ras is frequently mutated [11]. Frequent K- Ras 
mutations in various carcinomas are quantitatively detected and analyzed that 15%-20% in non- 
small cell lung carcinoma [12], 40% in colon adenomas [13], 95% in pancreatic ductal 
adenocarcinoma [14] are caused by K-Ras mutation creating it most common human 
oncoprotein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7: frequency of Ras mutation in human tumors 
RAS 
  K- ras 
H-ras N-ras 
15-20% NSCLA, 40% colon adenomas, 
95% pancreatic ductal adenocarcinoma 
Bladder, 
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tumors [15,16] 
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Codon specificity of Ras isoform mutations: 
Codon 12, 13 and 61 of the primary nucleotide sequences of all three isoforms of Ras 
gene areidentified as three hotspots for oncogenic mutations. Inhibition of GTP hydrolysis due to 
these codon specific mutation leads to diminish GTPase activity or modulation in guanine 
exchange [17]. About 99% of K-Ras mutation at codon 12  and very few mutations (about 1%) at 
codon 61 occurs whereas in N-Ras 35% at codon 12 and 60% at codon 61 was observed and a 
very high percentage of mutation about 54% at codon 12, 34.4% at codon 61 and 9% at codon 13 
in H-Ras was detected [11]. The mutation patterns within the codon are also distinctive. From 
mutation spectra it is clear that G12D, G12V, Q61K, Q61L and Q61R mutations are predominate 
over others.G12D is predominately mutated at codon 12 in K-Ras whereas G12V is favored by 
H-Ras [18]. Aggressiveness of tumors depends on K-Ras mutation. Survival rates of K-Ras 
G12R andG12A mutations were worst than G12V or G12S mutation in pancreatic ductal 
adenocarcinoma. In colon cancer K-Ras gene is associated most often in codon 12 (28%) and 13 
(8%) on exon 1whereas less frequently at codon 61[19]. Here substitution from Gly to Val in 
codon 12 has been occurred more frequently in primary metastasis carcinoma suggesting as more 
aggressive phenotype in colorectal carcinoma [20] but in codon 13 mutation from Gly to Asp has 
been observed and it shows the reduced survival rate in this cancer type [21]. 
 
Isoform specific Ras signaling: 
 
Ras isoforms interacts differentially with the positive and negative regulators of Ras cycle 
including Ras-GAP110 and RasGEF isoform. It is reported that H-Ras and R-ras but not N-Ras 
or K- Ras are activated by RasGRF1 [22] whereas in other studies it has been reported that Ras 
GRP2IS involved in activation of N-ras and K-Ras but not H-Ras[23]. GDP/GTP exchange in all 
three forms of Ras isoforms i.e. N-Ras, H-Ras,and K-Ras isoform were induced by Sos GEF but 
have different degree of potency in hierarchy H-RAS> N-Ras> K-Ras [24]. Raf-MEK-ERK 
kinase cascade and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB)/Akt 
pathway are the most important proliferation inducing signaling cascade that promotes cell 
survival. Different Ras isoforms act differentially in order to activate these pathways. In vitro 
studies shows that K-Ras has high efficiency to recruit Raf-1 to plasma membrane and thus 
activates its kinase activity  showing that it is the best activator of Raf and Rac whereas H-Ras is 
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more strongly coupled to PI3K [25]. H-Ras and K-Ras have highest ability to induce and activate 
NFkB than N-Ras. It has been also reported that cyclopentenone15-deoxy-Δ12,14-prostaglandin 
can activate H-Ras but not K-Ras and N-Ras by forming covalent adduct which does not occur in 
K-Ras and N-Ras. So the plethora of cellular responses which is activated by different Ras 
isoforms can depend on a particular set of effectors which are preferentially activated and the 
intensity and amplitude of that activation which may itself undergo negative of positive 
differential modulation. For example it is reported that calmodulin has been involved in the 
downregulation of Ras-ERK signaling pathway and only K-Ras has the capacity to bind with 
calmodulin but not H-Ras or N-Ras showing existence of differential mechanism of negative 
regulation among different Ras isoforms [26]. In NSCLC (non-small cell lung cancer) only 21% 
mutation in K-Ras gene in codon 12 and 13 were identified [27] but in case of breast cancer 
Hollestelle at al. found only 12.5% [28] mutations  whereas Sanger COSMIC database version 
28 (http://www.sanger.ac.uk/genetics/CGP/cosmic/) records only a 5% [29].From this it was 
analyzed that K-Ras are less frequently mutated, suggesting that K-Ras gene mutation is least 
important in breast cancer carcinogenesis as compared to other forms of cancer.  
 
K-Ras in human cancer: 
The K-Ras gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene 
encoding K-Ras which is a small GTPase transductor protein which is involved in the cell cycle 
regulation. It contains 188 amino acids having molecular weight 21.6kD. KRAS1 and KRAS2 
are two copies of K-Ras gene in human genome located at chromosomes 6 and 12 respectively 
[30]. An allelic loss of chromosome 12p12-13 region and KRAS gene mutation generally occur 
in human cancer[31]. K-Ras 1 is a pseudogene which is derived from KRAS2 by alternate 
mRNA splicing hence it is officially known as KRAS1P [32]. KRAS gene has 6 exons out of 
which 2, 3 and 4 are invariant coding exon. During alternate splicing exon 5 can be skipped, 
generating two isoforms KRASA and KRASB whereas 6
th
 exon C terminal region in KRASB 
but untranslated in KRASA. This protein is in inactive state until it interacts with GTP. Any 
mutations in the K-Ras gene weaken the capability of the K-Ras protein to switch between active 
and inactive states results in cell transformation and raise the resistance to chemotherapy and 
biological therapies which targets the receptors of epidermal growth factor.Usually wild type K-
Ras promotes cell cycle progression acting as tumor suppressor but mutation in this gene 
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increases the abnormal level resulting in acquiring its oncogenic properties and seems to be 
involved in the development various tpes of cancer in humans. Oncogenic mutation prevents 
GTP hydrolysis causing the activation of RAS molecules permanently. Mutated K-Ras gene 
expression in fibroblasts results in augment of expression of metalloproteinase 2 (MMP2) in the 
matrix which ultimately enhance the cancer cell invasion [33]. Overexpression of mutated form 
of K-Ras cause the inhibition of glycosylation of the intigrinβ1 chain causes the alternation in 
polarization and hence enhances the adhesiveness of colon cancer cells [34].  
 
 K-Ras gene mutation have important role in carcinogenesis depending upon the cells and 
tissue involved.  In cancer cells these mutation frequently occurs on position 12 and 13 in exon 1 
and less frequently in codon 61, 63,117,119, and 146 [35, 36]. Mutation in codon 12 of K-Ras 
gene causes the encoded protein “ice up” in its active state for much more longer period of time 
than in non- mutated form resulting in substitution in amino acids 116,117, 119and 146 causing  
the reduction of nucleotide affinity of K-Ras protein, thereby affecting the GDP/GTP exchange 
rate [34]. Overexpression of mutant K-Rasallele can be induced by loss of p16INK4 (CDKN2A), 
p19INK4 (CDKN2D), or p53 [37] and deletion of wild type allele results in transforming activity 
of KRAS oncogene. 
 
PI3/ AKT signaling cascade in tumor progression: 
Normal mammary epithelial cells transformed into cancer cells in a multistep 
development with alteration in signaling cascade conferring an imperative survival and growth 
advantages to malignant cells. Phosphatidylinositol 3-kinase (PI3K) pathway is a key mediator 
of cell growth andits metabolism, affected bygenetic alterations at different stages becoming a 
crucial cascade for cancer progression which outcome in a therapeutictarget which can act 
against breast cancer. This pathway is the most frequently mutated and genetically altered in 
excess of 70% of breast cancer with the amplification or alteration of genes which encodes PI3 
catalytic subunit p110α (PIK3CA) and p110β (PIK3CB), the PI3K regulatory subunit p85α 
(PIK3R1), receptor tyrosine kinase such as HGR2, ERBB2 and fibroblast growth factor receptor 
1, the PI3K activator K-Ras, the PI3K effectors AKT1, AKT2, and phosphoinositide- dependent 
kinase 1 (PDK1), and loss of the lipid phosphatase PTEN (phosphatase and tensin homo log) and 
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INPP4B (inositol polyphosphate-4-phosphatase, type II [38]. These genetic alterations in various 
components of PI3K signaling cascade are summarized in table 2. 
 
Table 2: Genetic alteration in PI3K signaling Pathway 
 
GENE 
 
 
MODIFICATIONS 
 
COMMENTS 
 
CANCER TYPE 
 
REFERENCES 
PTEN Loss of function by 
somatic mutation 
Truncation, loss 
of phosphatase 
activity 
Bladder, brain, 
breast, cervical, 
colorectal, 
endometrial, gastric, 
head and neck, 
kidney 
 
COSMIC, [39] 
Epigenetic silencing Transcriptional 
repression by 
promoter 
hypermethylation 
Breast, colon, 
melanoma 
[40], [41], [42] 
PIK3CA Gain of functionby 
somatic  mutation 
Exon 9 helical 
domain and exon 
20 catalytic 
domain. 
Breast, colorectal, 
glioblastoma, 
endometrial, 
cervical,  
lymphoma, ovarian, 
pancreatic, prostate, 
thyroid 
COSMIC [43], 
[44] 
Amplification Increased protein 
level and its 
activity 
Breast, cervical, 
gastric, lung, 
ovarian, prostate 
[45], [46], [47] 
AKT1 Gain of function by 
somatic mutation 
Pleckstrin 
homology 
domain, 
membrane 
localization, and 
constitutive 
activation 
Breast, colon, 
endometrial, 
melanoma, ovarian 
[48], [49] 
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AKT2 Gain of function by 
somatic  mutation, 
amplification 
Kinase domain 
mutation 
colorectal [50], [51] 
AKT3 Gain of function by 
somatic mutation 
Pleckstrin 
homology 
domain, 
membrane 
localization, and 
constitutive 
activation 
melanoma [49] 
PDK1 Gain of function by 
somatic  mutation 
Kinase domain 
mutation 
colorectal [50] 
 
PTEN works antagonistically to PI3K. I possesses protein tyrosine phosphatase activity 
and lipid phosphatase capable to cleave 3’phosphate group from PI(3,4,5)P3 which is necessary 
to function as tumor suppressor. Inactivation of PTEN tumor suppressor gene is the most 
common genetic modification in the PI3 signaling cascade leading to the loss of lipid 
phosphatase activity which cause the accumulation of PIP3 [53,54]. Homozygous and 
hemizygous deletion of PTEN are seen in many human cancer cases. Transcriptional repression 
and epigenetic silencing of PTEN through hypermethylation at promoter region results in PTEN 
inactivation [40,41]. At present somatic mutation in PIK3CA has been studied in various 
different forms of cancers like breast, colon, endometrial cancer and glioblastomas. Exon 9 and 
20 are the two hot spots for these mutations [43,44]. The catalytic domain of p110α is encoded 
by exon 20 and any type of mutation in this domain may constitutively activate its enzymatic 
activity whereas the helical domain of p110α is encoded by exon 9 and mutations at this region 
can de-repress an inhibitory interaction between the N-terminal SH2domain of p85 and the p110 
α catalytic subunit [55,56].  Expression of these PIK3CA mutants leads to raised oncogenic 
potential in vitro and in vivo,resulting in constitutive signaling along the PI3K pathway in the 
absence of growth factors and therefore seems to obviate the usual obligate communications with 
tyrosine phosphorylated RTKsand/or adapters [57]. Mutation in p85 regulatory subunit PIK3R1 
are also identified in various human cancer forms including colorectal cancer, glioblastomas, 
ovarian cancers resulting in truncation or in frame shift deletion on inter- SH2 domain of 
 17  
 
p85α[57]. AKT family including Akt1, Akt2 and Akt3 are also undergo mutation and were 
recognized in human cancer. A single amino acid replacement, E17K on PH domain of Akt1 was 
identified in breast, endometrial, ovarian, colorectal cancers as well as melanomas whereas 
E17K mutation in Akt3 was identified in melanomas [58]. 
PI3K activates downstream RTK signaling in normal epithelial cells but often mutated, 
overexpressed or amplified resulting in aberrant activation of PI3K in cancerous cells. The 
activation of PI3K by epidermal growth factor receptor (EGFR) in lung cancer harbors somatic 
activating mutations in EGFR and by human epidermal growth factor receptor 2 (HER2) in 
breast cancer with HER2 amplification [59]. 
 
PI3 pathway AND breast Cancer Subtype: 
 Luminal A, luminal B, HER2-enriched, and basal like tumors are sub types of breast 
cancer are grouped on the basis of their gene expression and the frequency of aberration of PI3K 
varies among these different sub types. Upto 40% of PIK3CA mutations have been founds in 
hormone receptor positive breast cancer showing the most frequent aberration in PI3K pathway. 
Here the mutation is associated with mTORC1 signaling. Mutations due to Akt activation are 
linked to preliminary tumorigenesis with posterior inhibition of invasion and metastasis. 
Enhanced PI3K activities were found in basal- like tumors i.e., triple negative for ER, PR and 
HER2 through PTEN loss [60]. 30% PTEN loss were recorded in basal- like breast cancer and 
cause MEK inhibition [61]. In 20-25% of human breast cancer HER2 are amplified mainly 
through the PTEN loss [60]. In ES cells and in embryonic fibroblast PTEN is inactive resulting 
in increased level of PIP3 [62]. Deficiency of PTEN led to enhance the phosphorylation and 
activation of Akt/PKB pathway ultimately increase the phosphorylation of BAD and promoted 
PTEN (-/-) cell survival [63] 
 
Clinical uses of PI3K cascade inhibitors: 
The upstream and downstream effectors of PI3k pathway comprise a potential target for drug 
development in breast cancer. Agents inhibiting this pathway at any level unaccompanied or in 
combination with chemotherapy, radiations are clinically used. Wortmannin and LY294002 are 
two best inhibitors.Wortmannin derived from Penicilliumwortmanninis a natural inhibitor which 
binds irreversibly to PI3K enzymes resulting in covalent modification in lysine, compulsory for 
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catalytic activity whereas LY294002 is a synthetic drug capable of reversibly targeting PIP3 
family helps in decreasing proliferation and increasing apoptosis and in conjugation with Arg-
Gly-Asp peptides are used as multimodal Pan-Pi3k inhibitor [60]. In a study ita was found thatA 
constitutively active Ras mutant cells were radiosensitized by PI3K inhibitor LY294002 but does 
not any affect on the survival of cells with wild-type Ras  suggesting that AKT may be a 
potential target for raising the response to radiotherapy in breast cancer patients [64]. 
GSK690693 (GlaxoSmithKline) is an ATP-competitive AKT kinase inhibitor thattargets all three 
isoforms of AKT. Reconstitution PTEN reduces AKT phosphorylation hence induces the 
transactivation of p53 resulting in increase the p53 target gene expression in glioma cells [65]. 
Thus PTEN and LY294002 affected p53 activity in endothelial cells of human brain, suggests 
that they can suppress the cancer progression directly on tumor and endothelial cells and block 
tumor progression in vivo [65]. 
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OBJECTIVES 
 
 
1. To determine the effect of natural polyphenols like CURCUMIN and Epigallocatechin 
gallate (EGCG) on breast cancer cell line MD-MB-231. 
 
2. To analyze the change in gene expression of K-Ras and Akt1 in presence of curcumin 
and EGCG.  
 
3. To analyze the apoptosis inducing propensity of these agents in breast cancer cell line 
MDA-MB-231. 
 
4. To observe the cell survivability and proliferating capacity of MDA-MB-231 cell line in 
presence of curcumin and EGCG. 
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METHODS AND MATERIALS 
 
1) CELL LINES AND CELL CULTURE: 
 
We obtained the MDA MB-231 cell line from the National Centre for Cell Science (NCCS), 
Pune, India. The cells are known to be of epithelial breast adenocarcinoma origin, adherent and 
are triple negative. Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, 
2 mM L-glutamine, and 100 units/ml penicillin-streptomycin sulfate (Invitrogen) was used to 
maintain cells growth. First cells were washed with 1 ml of 1X PBS then PBS was decanted then 
500 µl of trypsine was added and left for 15 min. cells were observed under microscope. After 
that 1.5 ml of media was added. Cells were counted by using hemocytometer under 
microscope.Desired amount of cells were seeded. A treatment was carried out with curcumin and 
EGCG, all purchased from Sigma and added to the regular growth media under sterile 
conditions. These cells were cultured in a 37°C, 5% CO2 incubator.  
 
2) MTT ASSAY: 
 
Cell viability analysis and cytotoxicity studies were performed using the MTT assay based 
on the observation that the mitochondria in living cells can catalyze MTT molecules to a 
colorimetrically detectable dye. MTT assay works on the principle that yellow colored MTT is 
reduced to purple colored formazan in the mitochondria of living cells by active mitochondrial 
reductase enzyme.To determine the proliferative activity, MDA MB-231 cells were seeded in 
three 96-well plates at a density (3000 cells/well) based on the doubling time, with 200 μl growth 
media (10% FBS) and incubate for 24, 48 and 72 hrs in incubator with 5% CO2 concentration at 
37ºC. Cell seeding must be uniform in order to obtain a dose response effect of the drug. After 
24 hours existing media was removed, washed with PBS and replaced with media with various 
concentration of drugs (5-50µM for curcumin and 50-300µMfor EGCG) and was incubated for 
24, 48 and 72 hours at 37º C. MTT working solution was prepared having 0.8mg/ml. 100 μl as 
final concentration to detect the cell viability by diluting the stock solution (stock 5mg/ml PBS, 
PH 7.2) in growth medium without FBS. MTT working solution was added to each well and 
incubated for 4 hours in CO2 incubator. The media was removed carefully after incubation 
without disturbing formazan precipitate and 100 μl of 100% DMSOwas added to it. An 
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incubation of 25 minutes was carried out in dark and the colorimetric estimation of formazan 
product was performed at 570nm in an ELISA reader. The data was plotted against drug to 
calculate the optimal growth inhibitory concentration (IC50) of the drugs. 
 
3) ISOLATION OF TOTAL CELLULAR RNA 
 
The total cellular RNA was extracted from MDAMB-231cells using TRI reagent (Sigma), 
following the manufacturer's instructions. The drug treated cells (10
5
 cells) were washed with 1 
ml ice cold PBS and then trypsinized. 1ml of Tri reagent was added in a culture dish. After 
addition of the reagent, a homogenous lysate was formed by pipetting cell lysate several times. 
These samples were allowed to stand for 5 minutes at room temperature so that complete 
dissociation of nucleoprotein complexes takes place. 0.2ml of chloroform was added for per ml 
of TRI Reagent used,vigorously shaken for 15 seconds and incubated for 2–15 minutes at room 
temperature. This mixture was then centrifuged at 12,000 g for 15 minutes at 4ºC to separate the 
mixture into 3 phases: a red organic phase (containing protein), an interphase (containing DNA), 
and a colorless upper aqueous phase (containing RNA).The upper aqueous phase was transferred 
to a fresh tube without disturbing interphase and 0.5 ml of isopropanol was added per ml of TRI 
Reagent and mixed. The sample was allowed to stand for 5– 10 minutes at room temperature and 
centrifuged at 12,000 g for 10 minutes at 4ºC. The RNA precipitate formed a pellet on the side 
and bottom of the tube. The supernatant was removed and 1 ml of 75% ethanol per 1 ml of TRI 
Reagent was added to wash RNA pellets. The sample were mixed by vortexing and then 
centrifuged at 7,500 g for 5 minutes at 4ºC. Then the RNA pellets were briefly dried for 5–10 
minutes by air drying. 40µl of DEPC treated water was added and mixed by repeated tapping. 
The RNA was stored at - 20° C for further use or immediately processed for cDNA synthesis. 
 
4) QUANTIFICATION OF THE TOTAL CELLULAR RNA 
Final preparation of RNA was analyzed using a nano-drop UV spectrophotometric analyzer. 
For analysis 2µl of RNA mixed with DEPC water was taken and put on nano drop cuvette. 
260/280 and 260/230 ratio was noted. It was likely that a standard preparation of RNA should 
have a 260/280 ratio of 1.8-2.0 and a 260/230 ratio of less than 260/280 ratio which indicates the 
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preparation to be free from proteins and oligo-peptides contamination The extracted RNA was 
run on a denaturing agarose gel and the quantity of RNA estimated from the band intensity.  
. 
5) cDNA SYNTHESIS AND EVALUATION: 
First strand cDNA was synthesized using Thermo Scientific Revert Aid First Strand 
cDNA Synthesis Kit. In PCR tube 1µl of oligo (dT)18 primer,1 µg of total RNA(drug 
treated) was taken and the volume was made up to 12 µl with the addition of nuclease free 
water. The mixture was gently mixed with pipetting and was briefly centrifuged. Then the 
mixture was incubated at 65°C for 5 minutes. After 5 minutes, the tubes containing mixture 
was snap cooled on ice. Then to this 12 µl mixture, 4 µl of 5X Reaction Buffer, 1 µl of  
RiboLock RNase Inhibitor (20 µg/ µl) ,2 µl of 10 mM dNTP Mixture and1 µl of RevertAid 
M-MuLV Reverse Transcriptase (200 µg/ µl) was added. The total volume of the mixture 
now became 20 µl. All the steps were performed while kept on ice. The total mixture was 
mixed thoroughly with gentle pipetting and spins down for few seconds to ensure proper 
mixing. Then the mixture was set for reverse transcriptase-PCR with incubation at 42°C for 
60 minutes followed by end incubation at 70°C for 5 minutes. The cDNA synthesized from 
the RNA was stored in ice at -20°C for further use. 
 
6) qRT-PCR ANALYSIS 
Real time Polymerase Chain Reaction or qRT- PCR is a method that allows exponential 
amplification of DNA sequences and simultaneously quantitates differences in mRNA 
expression. This system includes a DNA binding cyanine dye such as SYBR green that 
specifically binds to the major groove of double strand DNA but not to the single stranded DNA. 
SYBR green binds to the amplicons accumulated during PCR process which is proportional to 
the fluorescence emission of the dye. One reference dye (ROXdye) was used to serve as an 
internal reference for normalization of the SYBR green fluorescent signals.ROX dye allows for 
correction of well-to-well variation due to pipetting inaccuracies and fluorescence fluctuations. 
Four genes were taken for the experiment, three of which were test genes and one was 
housekeeping gene as a reference. Housekeeping gene are generally taken as reference genes to 
check for the expression of test genes i.e. how much fold the test gene’s expression has increased 
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or decreased with respect to normal gene expression. For this experiment the test genes were K-
Ras, Akt1 and reference gene used was β-actin.  
The total reaction volume prepared was 5 μl. 
Calculation: 
3genes were taken, therefore, 
              3 genes x 3 replicates×2 treatment = 18 reactions~20 reactions (to avoid        
inaccuracy due to pipette error) (12 reactions for each treatment) 
20 reactions x 5 μl = 100μl total volume was to be prepared. 
SYBR ® Green master mix dilution: 
The stock SYBR ® Green master mix solution was of 2X concentration(containing optimized 
mixture of SYBR green dye+MgCl2 +dNTPs+ Taq DNA Polymerase+ qPCR Reaction buffer) 
and from this working solution of 1 X concentration was taken.  
 2X x (? µl) = 1X x 100µl  
=> (? µl) = 1X x 100µl / 2X  
= 50µl  
SYBR ® Green master mix= 50µl 
Reference dye: 
For 100 µl of mixture reference dye taken, is 1 µl.  
Hence for 130 µl reaction mixture reference dye taken was,100 µl/100=1 µl 
cDNA was diluted at 1:20 ratio with addition of nuclease free water. 
For each reaction we required 1μl of diluted cDNA (EGCG treated and curcumin treated). 
Therefore, for 20 reaction= 1x20=20μl (for each treatment 20 μl template was needed.) 
Primer:  
The stock solution of primer contained 10μM, from which we required 500nM for each reaction 
10 μM x (? μl) = 500x10 -3μM x100 
=> (? μl) = 500x10 -3μM x100 / 10 μM 
= 5μl(each for forward and reverse primer) 
Reference dye=1 µl 
Forward Primer=5 µl 
Reverse primer= 5 µ 
Template=20 µl  
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Autoclaved distilled water = 19µl 
Total= 50µl 
Then a semi master mix was prepared with the addition of SYBR® Green master mix + 
Reference dye +water= (50 +1+19) μl= 70μl (for 3 genes) 
 
                                            23.33μl   23.33μl23.33μl 
Forward Primer= +1.67 
Reverse Primer= +1.67 
                              Total= 26.67 (for 2 treatment) 
 
13.34μl13.34μl(for 5 μl of reaction 1 μl template is needed,  
For 13.34μl of reaction template needed= 13.34/5=2.67) 
 Template=    + 2.67+ 2.67 
 Total= 16.01 μl (for each triplicate) 
 
 
5.33 μl   5.33 μl   5.33 μl 
For Real time PCR analysis mainly 2 types of primers are used: Forward primer and reverse 
primer. The primers were specifically designed with the help of NCBI primer blast tool.The 
primer sequence, their melting temperature and product length is shown below in table no.3:  
 
TABLE 3: Table showing the sequence of the forward and reverse primers 
NAME OF 
THE PRIMER 
TYPE SEQUENCE PRODUCT 
LENGTH 
 
K-RAS 
Forward 5'ACTGGGGAGGGCTTTCTTTG3' 20 
Reverse 5'GGCATCATCAACACCCTGTCT3' 21 
 
AKT1 
Forward 5’ACCTCTGAGACTGACACCATG3’ 21 
Reverse 5’CACTGGCTGAGTAGGAGAAC3’ 20 
 
β- actin 
Forward 5’CTGGAACGGTGAAGGTGACA3’  20 
Reverse 5’AAGGGACTTCCTGTAACAACGCA3’  23 
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Real-time PCR was carried out in Eppendorf Masterplex Real Time PCR. The experiment was 
set up with the following PCR program. The threshold frequency taken was 33%. The cycle 
temperatures taken were as follows: 
 
Table 4: Cycle temperature and time for qRT-PCR 
Stage Temperature (°C) Time Cycle 
 
Stage 1 
 
 
95 
 
20sec 
 
            1 
 
Stage 2 
95 
55 
68 
15sec 
15sec 
20sec 
           40 
 
Stage 3 
95 
60 
95 
15sec 
15sec 
15sec 
            1 
 
The melting curve was analysed by the inbuilt software and the change in relative gene 
expression with respect to β actin was detcted as fold change at logarithmic scale. 
 
 
7) ANALYSIS OF CHROMATIN CONDENSATION BY HOECHST 
33342 STAIN 
 
About 1 X 10
4
 cells were seeded in a Petri-plate and after 24 hours of seeding they were 
treated with curcumin and EGCG. After 24 hours of drug treatment treated cells were stained 
with 1 mg/ml of Hoechst 33342 stains and allowed to incubate for 10 min at 37°C and the 
images were taken under UV filter using Epi-fluorescent Microscope (Nikon TE 2000E) at 400X 
magnification with an excitation wavelength of 355-366 nm and an emission wavelength of 465-
480 nm. To analyze the percentages of apoptotic nuclei, condensed nucleus was counted against 
total number of nucleus in the field. 
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8) COMET ASSAY TO MEASURE THE DNA DAMAGE  
 
Comet assay is a gel electrophoresis with fluorescence microscopy based method used to 
visualize migration of DNA strands and to measure DNA damage from individual eukaryotic 
cells.Circular comet head contains undamaged DNA having high molecular weight and the 
comet tail represents damaged DNA. Longer and brighter tail shows higher level of DNA 
damage.  
 
8.1) Agarose preparation 
Two water baths were equilibrated at 40 °C and 100 °C respectively. Than 1% low 
gelling-temperature agarose was prepared by mixing powdered agarose with distilled water in a 
glassbeaker or bottle. The bottle was placed in the 100 °C water bath for several minutes and was 
transferred into a 40 °C water bath.  
8.2) Slide Precoating 
Agarose-precoated slides were prepared by dipping the slides into molten 1%   agarose 
and wiping one side clean. It is best to work in a low-humidity environment to ensure agarose 
adhesion. Agarose was allowed to air-dry to a thin film. Slides can be prepared ahead of time and 
stored with desiccant.  
8.3) Sample Preparation 
A single-cell suspension was prepared using enzyme disaggregation or mechanical 
dissociation. The cells were kept in ice-cold medium or phosphate-buffered saline to minimize 
cell aggregation and inhibit DNA repair. Using a hemocytometer or particle counter, cell density 
was adjusted to about 2 × 10
4
cells/ml in phosphate-buffered saline lacking divalent cations. 
Slides were labeled on frosted end using a pencil. 0.4 ml of cells into a 5 ml plastic disposable 
tube was pipette out. 1.2 ml 1% low-gelling-temperature agarose at was added at 40 °C. 1.2 ml 
of cell suspension onto the agarose-covered surface of a pre-coated slide was mixed by vigorous 
pipetting. Agarose was allowed to be gel for about 2 min. 
 
8.4) Lysis and Electrophoresis 
After agarose has gelled, slides were submerged in a covered dish containing A1 lysis 
solution [1.2M NaCl, 100mM Na2EDTA, 0.1% sodium lauryl sarcosinate, 0.26M NaOH 
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(pH.13)]. Samples were lysed overnight (18−20 h) at 4 °C in the dark. After overnight lysis, 
slides were removed carefully and submerge in A2 rinse solution [0.03M NaOH, 2mM na2EDTA 
(pH 12.3)] for 20 min at room temperature (18−25 °C). The process was repeated two times to 
ensure removal of salt and detergent. Care was taken for not allowing DNA to renature even 
briefly (i.e., by lowering pH below 12.3) until after electrophoresis, as this will result in DNA 
tangling and reduced migration. After these three rinses, slides were submerged in fresh A2 
solution in an electrophoresis chamber. The chamber was filled with a consistent volume of 
buffer that is about 1–2 mm above the top of the agarose. It was ensured that the chamber is level 
using a bubble leveling device. Electrophoresis was conducted in solution A2 for 25 min at a 
voltage of 0.6 V/cm. The current was about 40 mA using 20 V.  
 
8.5) Slide Staining  
Slides were removed from electrophoresis chamber and were rinsed and neutralizedin 
400 ml of distilled water. Slides were placed in staining solution containing 2.5 μg/ml of 
propidium iodide in distilled water for 20 min. Finally the slides were rinsed with 400 ml 
distilled water to remove excess stain. 
 
8.6) Slide Analysis 
Analyses of cells were done by examining at least 50 comet images from each   slide.  
Analyzing doublets or comets at slide edges should be avoided. Image analysis software was 
used to analyze individual comet images. 
 
9) DNA FRAGMENTATION ASSAY 
Culture media were collected and 1ml of trypsin was added to monolayer on 100mm dishes, cells 
were then scrapped and harvested (culture media and cell monolayer) by centrifugation at 2,500 
rpm for 5 min.  Cell pellets were then washed with 1X PBS.  100 µl of lysis buffer (1% NP-40 in 
20 mM EDTA, 50 mM Tris-HCl, pH 7.5) was added and kept for 10 sec in order to lyse the 
cells.  For the Preparation of 1µl of  lysis buffer 10% NP-40 100 ml, 200 mM EDTA 100 µl , 0.2 
M Tris-HCl (pH 7.5) 250 µl , D.W. 550 µl were added together. After adding lysis buffer the 
solution was centrifuged at 3,000 rpm for 5 min to obtain the supernatant 10 µl of 10% SDS 
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solution was added to pooled supernatant (final: 1% SDS),then it was treated with 10 µl of 50 
mg/ml RNase A (final 5 mg/ml) and incubated for 2 h at 56 C. after that 10 µl of 25 mg/ml 
Proteinase K (final 2.5 mg/ml) was added and again incubated for 2 h at 37 C. To this 1/2 vol. 
(65 µl) of 10 M ammonium acetate was added. 2.5 vol. (500 µl) of ice-cold ethanol was then 
added and mixed thoroughly and allowed to stand for 1 h in – 80 C freezer so that ethanol was 
precipitated. The solution was centrifuge for 20 min at 12,000 rpm, and then the white pellet was 
washed with 200 µl 80% ice cold ethanol and allowedto air-dry for 10 min at room temperature. 
The pellet was dissolved with 50 µl of TE buffer. DNA concentration was determined by taking 
absorbance at 260 and about 4 µg of the same concentration of DNA was run in 2% agarose gel 
electrophoresis. 
 
10) COLONOGENIC CELL SURVIVAL ASSAY 
The colonogenic cell survival assay determines the capacity of cells to produce its clone. 
Usually from a single cell a colony of 50 or more cells are formed. Single cell suspensions were 
prepared by trypsinization. Then these cells were washed with phosphate buffered saline and 
incubated with a 0.05% trypsin 5-10 minutes. After that 1.5 ml of Dulbecco's modified eagle 
medium (DMEM) containing 10% fetal bovine serum is added to neutralize the trypsin. The cells 
were detached by pipetting up and down. Cells were counted using a hemocytometer. These cells 
were treated with different drugs like curcumin and EGCG having 25 µl and 200 µl 
concentration respectively and then seeded in triplicate into petri-dishes with densities varying 
from  600-1000 cells/ dish so that we get 50–200 colonies/dish. The cells were then culturedin a 
37°C, 5% CO2 incubator for 7-10 days. Then slides were dipped in 1 ml of 1X cold PBS and 
kept for 10 min followed by dipping in 1 ml absolute cold methanol for 10 min.  Finally the 
clones were stained with 0.05% crystal violet and kept for 10-15 min and then destained by 
washing with water for 4 times. These slides were observed under Epi- fluorescent microscope 
(Nikon TE 2000E) at 400X magnification with an excitation wavelength of 355-366 nm and an 
emission wavelength of 465-480 nm.  
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11) SOFT AGAR ASSAY 
It is an anchorage independent growth assay used to detect malignant transformation of cells.  
 
10.1) Preparation of base agar 
0.7% agar was melted in a microwave. Then 2X DMEM with 20% FBS and antibiotics 
was taken in a falcon tube. Equal volumes of these two solutions were mixed to get 
0.7%Agar+1X DMEM+ 10% FBS. From this mixture 1.5 ml was taken and added to each 35mm 
petri dish and set aside for 5-10 min to allow agar to solidify. 
10.2) Preparation of top agarose 
0.8% Agarose was melted in a microwave. 2X DMEM with 20% FBS was taken in a 
falcon.The adherent cells were trypsinized to release them and number of cells per ml was 
counted. 5,000 cells /plate were required for each 35 mm Petri dishes.  These cells were then 
treated with different drugs like curcumin and EGCG. 0.1ml of cell suspension was added to 
10ml tubes. 35mm base agar dishes were labeled appropriately. 3 ml of 2X DMEM +10%or 20% 
FBS and 3 ml of 0.7% agarose was added to a tube of cells for plating. They were mixed gently 
by swirling and 1.5 ml was added to each of the three replicate plates. Then these plates were 
incubated at 37 ºC in a humidified incubator for 10 to 20 days. The cells were fed 1-2 times per 
week with cell culture media. After 10-20 days plates were stained with 0.5 ml of 0.005% of 
crystal violet for more than 1 hour. After staining colonies were counted using a dissecting 
microscope. 
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RESULT AND DISCUSSION 
 
1) CELL VIABILITYASSAYBY MTTMETHOD 
 
Breast cancer cell line MDA MB-231 viability after the treatment of drugs like curcumin and 
EGCG was determined by doing MTT assay. In order to determine the optimum dosage, 
different concentrations of the drugs were considered and the treatment was done for different 
time intervals i.e., 24 hours, 48 hours and 72 hours. The IC50 value for the both drug were 
calculated.The result obtained from MTT assay is shown in figure 8 and 9: 
 
 
 
 
Fig 8: Graphical representation of curcumin treated MDA-MB-231cells 
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Fig 9: Graphical representation of EGCG treated MDA-MB-231cells 
 
From this graphical data it can be inferred that cell viability declined progressively with an 
increased dose of natural polyphenols, curcumin and EGCG.From this assay 25 µM of curcumin 
and 200 µM of EGCG can be taken as optimum dose for further analysis. 
 
2) ISOLATION OF TOTAL CELLULAR RNA BY TRIZOL METHOD 
The total cellular RNA was isolated following the manufacturer’s instructions by Tri-reagent 
(Sigma). The isolation was almost pure and in good yield as the reading in Nanodrop 
spectrophotometer showed the 260/280 absorption ratio was 2.01 and the 260/230 absorption 
ratio above 1.8 and the 260/230 absorption ratio was less than 260/280 ratio for all the samples 
quantified. The concentration and ratio for both drug treated cells were summarized in the table 
given below: 
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TABLE 5: RNA concentration and ratio for the control and drug treated cells 
 
 
SAMPLE 
 
CONCENTRATION 
(µg/ml) 
 
260/280 RATIO 
 
260/230 RATIO 
control 909.3 1.9 1.91 
Curcumin treated cells 617.0 2.01 2.05 
EGCG treated cells 272.9 1.96 1.42 
 
 
3) cDNA SYNTHESIS AND qRT-PCR 
In general qRT-PCR data confirmed that K-Ras and Akt1 genes are upregulated in breast 
cancer cell line MDA MB-231. But when these cells were treated with curcumin and EGCG 
their expression was downregulated. 
 
 
  
Fig 10:RT-PCR analysis of K-Ras and Akt-1 in presence of curcumin in MDA-MB 231 
Cell line  
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Fig 11: RT-PCR analysis of K-Ras and Akt-1 in presence of EGCG in MDA-MB 231 
Cell line 
 
 
4) ANALYSIS OF CHROMATIN CONDENSATION BY HOECHST 
33342  STAIN 
 
Nuclear chromatin condensation in drug treated MDA-MB-231 cell by Hoechst staining is a 
visually detectable assay to quantify the amount of apoptotic cells after drug treatment. After 
treatment with curcumin and EGCG for 0-24hr in a time dependent manner the MDA-MB-231 
cells were stained with Hoechst 33342 stain and analyzed for the chromatin condensation. The 
result indicates that there was formation of more condensed chromatin structures after treatment 
with EGCG and curcuminthan control in a time dependent manner. 
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Fig 12:Observation of Morphological changes in nuclei of treated MDA-MB 231 
cells by Hoechst staining 
 
5) COMET ASSAY TO MEASURE THE DNA DAMAGE  
 
MDA MB-231 cells in culture after treatment with curcumin and EGCG for 24hrs were 
analyzed for the amount of DNA damage by the comet assay. The results showed significant 
amount of DNA damage in EGCG treated cells and Curcumin treated cells as compared to the 
untreated control cells. The characteristic comet tail length, tail moment and tail DNA% suggests 
the amount of DNA damaged which are graphically represented and tabulated below. 
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Table no. 6: Analysis of comet assay of curcumin and EGCG treated cells 
 
Drug Drug 
concentration 
Tail length Tail moment Tail DNA % 
control 0μM 45 5.936982331 
 
13.1932940681554 
curcumin 25μM 130.4 21.32449134 
 
16.3531375332227 
EGCG 200μM 115.26 27.00348397 
 
23.42832203 
 
 
From this analyzed data obtained from curcumin and EGCG treated MDA-MB-231 cells by 
using softwareImageJ, we can plot a graph as shown below: 
 
 
 
Fig 13: Tail length of curcumin and EGCG treated cells showing DNA damage 
 
 
0
20
40
60
80
100
120
140
160
180
0 μM 25 μM Curcumin 200μM EGCG 
T
a
il
 l
en
g
th
 
TailLength
 36  
 
 
 
Fig 14: Tail moment of curcumin and EGCG treated cells showing DNA damage 
 
 
 
 
 
Fig 15: Tail DNA% of curcumin and EGCG treated cells showing DNA damage 
 
6) DNA FRAGMENTATION ASSAY: 
 
DNA fragmentation assay shows that untreated normal cells show a very high molecular 
weight DNA and remain intact near the lane whereas a ladder of equal size was seen in drug 
treated cells which show apoptosis. Densitometric analysis of ladder lanes were done using 
Image-J software which showed distinct peaks representing a single band on the gel, ranging 
from high to low molecular weight. 
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Fig 16: Analysis of apoptosis by DNA fragmentation assay 
 
 
 
Fig 17: Confirmation of DNA fragmentation in presence of corcumin 
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Fig 18: Confirmation of DNA fragmentation in presence of EGCG 
 
 
 
7) COLONOGENIC CELL SURVIVAL ASSAY  
MDA MB-231 cell’s survivability and proliferation was determined by performing colonogenic 
cell survival assay. This assay determines the reproductive death of cells after treatment of 
various drugs. From this assay it can be concluded that cell’s survivability was declined in the 
presence of drugs like curcumin and EGCG with respect to control having concentration 25 μM, 
200 μMand 0 μM respectively which are shown below in Figure no. 16 and 17.  
 
              
 
          Control                           curcumin                          EGCG 
 
Fig 19: Colonogenic cell survivability of curcumin and EGCG treated MDA-MB-231 cell 
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Fig 20: graphical representation of colonogenic cell survivability of curcumin and EGCG treated 
MDA-MB-231 cell  
 
 
8) Soft agar assay: 
 
Reduction in the colony formation and anchorage independent growth, is one of the hallmark 
of cell transformation by colonogenic assay was further analyzed by performing soft agar assay 
where the cells were grown in semi -solid media which mimics the in vivo condition.Anchorage 
independent growth is one of the hallmark of cell transformation, was determined by soft agar 
assay. The proliferation of curcumin and EGCG treated MDA MB-231 cells in a semisolid 
culture media after 1week was determined by this assay. After 1 week of culture of cells in 
semisolid media, the cells were analyzed by using software and it was inferred that the 
survivability and colony formation capability of MDA MB-231 was declined in the presence of 
curcumin and EGCG as shown in figure no 22 and 23.  
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Fig 21: Observation of colony formation in soft agar of curcumin and EGCG treated MDA MB- 
231 cells  
 
 
Fig 22: Analysis of Soft agar assay of curcumin and EGCG treated   MDA-MB 231 cells  
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CONCLUSION 
 
Apoptosis is a programmed cell death process, generally characterized by distinct 
morphological characteristics and energy dependent biochemical processes and considered as an 
important and vital component of many processes like normal cell turnover and cell death. This 
process is necessary to eliminate damaged and dangerous cells from the body and to keep body’s 
cell number constant. Inappropriate apoptosis may cause many human conditions including 
autoimmune disease, many types of cancer etc. PI3k/Akt and RAS/MEK/ERKsignaling cascade 
are most frequently mutated pathway in human cancer. Their genes are mutated in such a way 
that they cause deregulation in its effector pathway and various other transcription factors which 
control cell growth, proliferation, survival and migration. Usually K-Ras and AKT 1 are the most 
frequently mutated oncogene in human breast cancer. From this study it was observed that the 
expression level of these two genes were downregulated in breast cancer cell line MDA-MB-231 
when treated with two natural polyphenols curcumin and EGCG. MTT assay shows that 
curcumin and EGCG has more potential to reduce the cell viability but in case of curcumin IC50 
is obtained at very low concentration about 25µM as compared to EGCG which comes at 200 
µM. Also in the presence of curcumin and EGCG this cell line shows more condensed chromatin 
which is a key hallmark of apoptosis. This result was confirmed by performing comet assay by 
analyzing the tail length in pixel units. Large tail length was seen in the drug treated cells which 
is the main characteristic feature of DNA damage. Colonogenic and soft agar assay both can be 
done toidentify the colony formation capability of cells but soft agar assay has been done in a 
semi-solid growth media which mimics the in vivo condition. From these two assays it was 
concluded that very few numbers of colonies were formed in these two drugs treated cells, 
indicating the reduced rate of anchorage independent cell survivability and proliferation but on 
comparing these two drug treated cells, curcumin has more potential to reduce the colony 
formation and cell survivability. So it can be inferred that these two natural polyphenols can 
induce apotosis, inhibit proliferation and downregulates the level of oncogenes at transcriptome 
level.   
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